IFIH1 and dermatomyositis: Moreover, anti-MDA5+ dermatomyositis patients often receive treatment with high doses of glucocorticoids combined with immunosuppressants, which leads to increased susceptibility to opportunistic infections such as PJP and a poor prognosis [26–29].